2023
Absence of either Ripk3 or Mlkl reduces incidence of hepatocellular carcinoma independent of liver fibrosis
Mohammed S, Thadathil N, Ohene-Marfo P, Tran A, Van Der Veldt M, Georgescu C, Oh S, Nicklas E, Wang D, Haritha N, Luo W, Janknecht R, Miller B, Wren J, Freeman W, Deepa S. Absence of either Ripk3 or Mlkl reduces incidence of hepatocellular carcinoma independent of liver fibrosis. Molecular Cancer Research 2023, 21: 933-946. PMID: 37204757, PMCID: PMC10472095, DOI: 10.1158/1541-7786.mcr-22-0820.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseProgression of NAFLDHepatocellular carcinomaChronic inflammationLiver fibrosisMale miceMouse modelCholine-deficient high-fat dietFemale wild-type miceOncogenic pathwaysFatty liver diseaseMarkers of inflammationHigh-fat dietLow-fat dietDevelopment of inflammationValid therapeutic targetWild-type miceHepatic inflammationInflammation contributesLiver diseaseWT miceFemale miceSex-specific differencesInflammationTherapeutic target
2019
Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy
Abu-Sbeih H, Tang T, Ali F, Luo W, Neelapu S, Westin J, Okhuysen P, Foo W, Curry J, Richards D, Ge P, Wang Y. Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. American Journal Of Clinical Oncology 2019, 42: 789-796. PMID: 31478934, DOI: 10.1097/coc.0000000000000596.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAntineoplastic Combined Chemotherapy ProtocolsAsparaginaseBiopsy, NeedleCohort StudiesCytarabineDaunorubicinFemaleGastric MucosaGastritisGastrointestinal DiseasesHematologic NeoplasmsHumansImmunohistochemistryImmunotherapy, AdoptiveIncidenceMaleMiddle AgedPrognosisReceptors, Chimeric AntigenRetrospective StudiesRisk AssessmentSeverity of Illness IndexSex DistributionThioguanineConceptsChimeric antigen receptor T-cell therapyCytokine release syndromeGastrointestinal adverse eventsGI AEsT-cell therapyRefractory colitisEncephalopathy syndromeRelease syndromeAdverse eventsHematologic malignanciesDiffuse large B-cell lymphomaLarge B-cell lymphomaGastrointestinal tract inflammationGrade 1 diarrheaOnly symptomatic treatmentStandard of careCertain hematologic malignanciesB-cell lymphomaCART infusionAbdominal distensionAbdominal painBloody stoolGastrointestinal symptomsMedian durationExperienced diarrhea